Short Interest in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Expands By 20.8%

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) was the target of a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 352,300 shares, an increase of 20.8% from the February 28th total of 291,600 shares. Based on an average daily trading volume, of 141,900 shares, the short-interest ratio is currently 2.5 days. Approximately 0.6% of the shares of the company are short sold.

Insider Transactions at Nautilus Biotechnology

In other Nautilus Biotechnology news, CEO Sujal M. Patel bought 53,300 shares of the stock in a transaction that occurred on Wednesday, March 19th. The shares were purchased at an average cost of $0.99 per share, for a total transaction of $52,767.00. Following the transaction, the chief executive officer now directly owns 10,117,788 shares in the company, valued at $10,016,610.12. The trade was a 0.53 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 40.50% of the company’s stock.

Hedge Funds Weigh In On Nautilus Biotechnology

A number of hedge funds have recently modified their holdings of NAUT. Virtu Financial LLC acquired a new position in Nautilus Biotechnology in the 4th quarter worth about $28,000. Cubist Systematic Strategies LLC acquired a new stake in Nautilus Biotechnology in the fourth quarter valued at approximately $34,000. The Manufacturers Life Insurance Company bought a new stake in Nautilus Biotechnology in the third quarter worth approximately $67,000. Squarepoint Ops LLC bought a new stake in Nautilus Biotechnology in the fourth quarter worth approximately $44,000. Finally, SG Americas Securities LLC increased its stake in shares of Nautilus Biotechnology by 56.3% during the 4th quarter. SG Americas Securities LLC now owns 27,483 shares of the company’s stock worth $46,000 after purchasing an additional 9,904 shares during the last quarter. 50.71% of the stock is owned by institutional investors and hedge funds.

Nautilus Biotechnology Price Performance

Shares of NAUT opened at $0.78 on Thursday. The stock has a market capitalization of $98.02 million, a P/E ratio of -1.52 and a beta of 1.25. Nautilus Biotechnology has a 12-month low of $0.78 and a 12-month high of $3.09. The firm’s 50 day moving average is $1.37 and its 200-day moving average is $2.01.

Wall Street Analysts Forecast Growth

NAUT has been the subject of a number of recent analyst reports. Guggenheim set a $2.50 target price on shares of Nautilus Biotechnology in a research report on Friday, February 28th. The Goldman Sachs Group cut Nautilus Biotechnology from a “neutral” rating to a “sell” rating and lowered their price target for the company from $2.25 to $1.75 in a research report on Thursday, December 5th.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.